Premium
Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
Author(s) -
Medeiros Bruno C.,
Chan Steven M.,
Daver Naval G.,
Jonas Brian A.,
Pollyea Daniel A.
Publication year - 2019
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25484
Subject(s) - medicine , myeloid leukemia , oncology , minimal residual disease , complete remission , disease , clinical trial , leukemia , chemotherapy , intensive care medicine
Optimization of post‐remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post‐remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post‐remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.